Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy

Harbour BioMed and Kelun-Biotech have received approval from China’s NMPA for their IND application for the HBM7575/SKB575 bispecific antibody intended to treat asthma. The antibody uses a dual mechanism of action and works to block the interaction between TSLP and its receptor. HBM7575/SKB575 blocks the interaction between TSLP and its receptor, inhibiting signalling pathways and Th2 immune cell activation. Credit: alicancomertpay / Shutterstock.com. Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration (NMPA) for their investigational new drug (IND) application for the HBM7575/SKB575 bispecific antibody intended to treat asthma. HBM7575/SKB575 is designed to target thymic stromal…

Source: Pharmaceutical Technology